Creative Medical Technology (NASDAQ:CELZ) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Creative Medical Technology (NASDAQ:CELZ) to a sell rating in a report published on Saturday.

Other research analysts have also issued research reports about the stock. Weiss Ratings upgraded shares of Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Creative Medical Technology Trading Down 7.6%

NASDAQ:CELZ opened at $1.21 on Friday. The company has a 50-day moving average of $1.18 and a 200-day moving average of $1.76. The firm has a market cap of $7.97 million, a price-to-earnings ratio of -0.58 and a beta of 1.95. Creative Medical Technology has a twelve month low of $0.62 and a twelve month high of $6.25.

Creative Medical Technology (NASDAQ:CELZ) last released its earnings results on Friday, August 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, research analysts forecast that Creative Medical Technology will post -1.18 earnings per share for the current year.

Hedge Funds Weigh In On Creative Medical Technology

Institutional investors and hedge funds have recently modified their holdings of the stock. Seros Financial LLC acquired a new position in shares of Creative Medical Technology in the second quarter worth $53,000. Jane Street Group LLC purchased a new stake in shares of Creative Medical Technology during the fourth quarter worth $59,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in Creative Medical Technology during the second quarter valued at $192,000. 1.42% of the stock is currently owned by hedge funds and other institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.